Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. BLZE
7. IBM
8. NKE
9. MU
10. ACN

Go back to Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections

Arbutus Biopharma (ABUS) Tops Q1 EPS by 14c

May 11, 2020 6:14 AM EDT

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.25), $0.14 better than the analyst estimate of ($0.39).

William Collier, President and Chief Executive Officer of Arbutus, stated, As we announced in March, preliminary results from an ongoing Phase 1a/1b clinical trial for our lead... More